Skip to content

Individualized Antiplatelet Therapy After Percutaneous Coronary Intervention for Acute Coronary Syndrome: Current SAPT Strategies and the Potential Role of Indobufen.

Oct 2026 · Cardiology in Review · 0 citations · 121 references
Medicine

TL;DR

Current evidence suggests that indobufen-based DAPT may provide comparable ischemic protection with fewer bleeding or gastrointestinal adverse events in selected PCI patients, particularly those with aspirin intolerance, gastrointestinal vulnerability, or high bleeding risk.

Abstract

Acute coronary syndrome requires effective antiplatelet therapy after percutaneous coronary intervention (PCI), while contemporary patients often present with overlapping ischemic and bleeding risks. This clinical complexity has shifted post-PCI management from fixed-duration dual antiplatelet therapy (DAPT) toward individualized strategies based on DAPT duration, single antiplatelet therapy (SAPT) selection, and aspirin withdrawal. Aspirin is traditionally the default maintenance agent after DAPT, although long-term aspirin use is limited by gastrointestinal intolerance, mucosal injury, and bleeding risk. P2Y12 inhibitor monotherapy represents an important aspirin-free strategy, with clinical application influenced by drug potency, genetic variability, tolerability, cost, and adherence. Indobufen, a reversible cyclooxygenase-targeting antiplatelet agent, has reemerged as a potential aspirin alternative by suppressing thromboxane A2 generation through a mechanism distinct from that of aspirin. Current evidence suggests that indobufen-based DAPT may provide comparable ischemic protection with fewer bleeding or gastrointestinal adverse events in selected PCI patients, particularly those with aspirin intolerance, gastrointestinal vulnerability, or high bleeding risk. These patients often present with multiple high-risk features that simultaneously elevate both ischemic and bleeding risks, underscoring the need for careful risk stratification. Most available studies have evaluated indobufen as an aspirin substitute within DAPT rather than as SAPT after DAPT discontinuation. From a pharmacoeconomic perspective, indobufen is more expensive than aspirin, although this must be weighed against potential benefits in bleeding reduction. Future randomized trials are needed to define the optimal DAPT-to-SAPT strategy and clarify the clinical position of indobufen in acute coronary syndrome-PCI.

View source

Similar papers

Open access Oct 2026

Clopidogrel or prasugrel vs. aspirin monotherapy for long-term secondary prevention after percutaneous coronary intervention for acute coronary syndrome

Optimal long-term antiplatelet monotherapy in patients with acute coronary syndrome (ACS) who underwent percutaneous coronary intervention (PCI) remains a subject of ongoing debate. In particular, it remains unclear whether different P2Y12 inhibitors provide comparable clinical benefits when used as long-term mon...

Y. Iwanaga, K. Kanaoka, K. Takegawa et al. · 0 citations
Review Open access Sep 2026

Personalised antiplatelet therapy during elective percutaneous coronary intervention in patients with chronic coronary syndrome: An international journal of cardiology expert consensus statement.

Oral P2Y12 inhibitors represent the mainstay therapy for the prevention of thrombotic complications in patients undergoing percutaneous coronary intervention (PCI) and coronary stent implantation. However, the onset of antiplatelet action of the oral P2Y12 inhibitors is affected by their need to be absorbed in the gast...

F. Pelliccia, Giuseppe Andò, P. Capranzano et al. · 0 citations
Review Open access Oct 2026

Standard versus extended dual antiplatelet therapy after pci in acute coronary syndrome: a systematic review and meta-analysis

The absence of benefit was confirmed both during overall follow-up and in landmark 12-month analyses, with a reduction observed only in repeat revascularisation, a softer endpoint, and findings support an individualised approach to DAPT duration rather than routine prolongation beyond one year.

A. Gasca, N. Murillo, S. Cordoba et al. · 0 citations
Open access Nov 2026

Potent P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the STARS DAPT randomized pilot trial.

BACKGROUND Dual antiplatelet therapy (DAPT) for 12 months is the current standard of care for patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). Recent evidence indicates that potent oral P2Y12 inhibitor-based single antiplatelet therapy (SAPT)...

J. F. Iglesias, B. Stähli, D. Heg et al. · 0 citations
Review Open access Oct 2026

Antiplatelet monotherapy maintenance strategies after percutaneous coronary intervention in patients with coronary artery disease at high bleeding risk: a network meta-analysis

Background The optimal antiplatelet monotherapy maintenance strategy after percutaneous coronary intervention (PCI) remains uncertain in patients with coronary artery disease at high bleeding risk, particularly among those not receiving oral anticoagulant therapy. We performed a network meta-analysis to compare the saf...

Xiao Zhang, Yu-Jie Wang, Y. Guo et al. · 0 citations
Open access Oct 2026

Aspirin or Clopidogrel Following Dual Antiplatelet Therapy in PCI-Treated Acute Coronary Syndrome Patients: A Real-World Population-Based Study

Background: Recent guidelines on Chronic Coronary Syndromes, for long-term monotherapy after acute coronary syndrome (ACS) or revascularization, have upgraded the recommendation for clopidogrel to the same strength as aspirin. We aimed to evaluate temporal trends and predictors of aspirin use compared to clopidogrel mo...

Luisa Ojeda-Fernández, M. Molteni, Patrick Prada et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.